AM6 Stock Overview
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Amicus Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.70 |
| 52 Week High | US$13.20 |
| 52 Week Low | US$9.25 |
| Beta | 0.76 |
| 1 Month Change | -8.49% |
| 3 Month Change | -15.65% |
| 1 Year Change | -6.73% |
| 3 Year Change | 16.17% |
| 5 Year Change | -17.70% |
| Change since IPO | -1.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| AM6 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.5% | -0.2% | 0.5% |
| 1Y | -6.7% | -22.8% | 1.3% |
Price Volatility
| AM6 volatility | |
|---|---|
| AM6 Average Weekly Movement | 5.5% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: AM6's share price has been volatile over the past 3 months.
Volatility Over Time: AM6's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 517 | Brad Campbell | amicusrx.com |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline.
Amicus Therapeutics, Inc. Fundamentals Summary
| AM6 fundamental statistics | |
|---|---|
| Market cap | €2.91b |
| Earnings (TTM) | -€141.31m |
| Revenue (TTM) | €372.28m |
7.8x
P/S Ratio-20.6x
P/E RatioIs AM6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AM6 income statement (TTM) | |
|---|---|
| Revenue | US$399.36m |
| Cost of Revenue | US$37.33m |
| Gross Profit | US$362.03m |
| Other Expenses | US$513.61m |
| Earnings | -US$151.58m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.51 |
| Gross Margin | 90.65% |
| Net Profit Margin | -37.96% |
| Debt/Equity Ratio | 242.1% |
How did AM6 perform over the long term?
See historical performance and comparison